• linkedin
  • Increase Font
  • Sharebar

    DAAs safely treat chronic kidney disease in HCV patients

    Sofosbuvir-based direct-acting antiviral (DAA) therapy is safe and effective in patients with chronic kidney disease who are infected with hepatitis C virus (HCV), according to a new study.

    HCV infection is common among patients with chronic kidney disease (CKD) and leads to accelerated progression to end-stage renal disease. Sofosbuvir is a potent DAA against HCV, however, a previous analysis of nationally collected data raised some concerns about a risk of acute kidney injury among more advanced kidney disease patients treated with the drug.

    “We found no signal of kidney injury with DAAs in advanced kidney failure. The glomerular filtration rate (GFR) remains stable on therapy,” Meghan Sise, MD, an instructor in medicine at Massachusetts General Hospital and study co-author, told Medical Economics.

    “In addition, these drugs are effective and may have a higher chance of a cure in patients with lower GFR. There was also an association between cure and GFR in the follow-up period, so when patients are cured of HCV infection, their kidney function could improve.”

    The researchers published their results online September 7, 2017, in the Clinical Journal of the American Society of Nephrology.

    Next: Study details

     

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow

    Poll